TY - JOUR
T1 - Changes in the homeostatic appetite system after weight loss reflect a normalization toward a lower body weight
AU - DeBenedictis, Julia Nicole
AU - Nymo, Siren
AU - Ollestad, Karoline Haagensli
AU - Boyesen, Guro Akersveen
AU - Rehfeld, Jens Frederik
AU - Holst, Jens Juul
AU - Truby, Helen
AU - Kulseng, Bard
AU - Martins, Catia
N1 - Funding Information:
The Liaison Committee for education, research, and innovation in Central Norway and the Norwegian University of Science and Technology (NTNU) provided funding. Allévo, Karo Pharma Sverige AB Sweden provided the VLED products (no commercial interest).
Publisher Copyright:
© 2020 Endocrine Society. All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - Objective: To compare appetite markers in reduced-obese individuals with a nonobese control group. Methods: A total of 34 adults with obesity who lost 17% body weight at week 13 and maintained this weight loss (WL) at 1 year were compared with 33 nonobese controls matched for body composition. Basal and postprandial subjective appetite ratings and appetite-related hormone concentrations (ghrelin, total peptide YY, peptide YY3-36, total and active glucagonlike peptide 1, and cholecystokinin) were measured in all participants and repeated at week 13 and 1 year in the weight-reduced group. Results: WL led to a reduction in prospective food consumption and an increase in feelings of hunger, fullness, and ghrelin secretion (basal and postprandial), but these new ratings were no different from those seen in controls. Postprandial concentrations of active glucagon-like peptide 1, total peptide YY, and cholecystokinin were lower in individuals with obesity at all time points compared with controls. Conclusion: The increased drive to eat (both subjective feelings of hunger and ghrelin concentrations) seen in reduced-obese individuals, both after acute and sustained WL, reflects a normalization toward a lower body weight. Overall, WL does not have a sustained negative impact on satiety peptide secretion, despite a blunted secretion in individuals with obesity compared with nonobese controls.
AB - Objective: To compare appetite markers in reduced-obese individuals with a nonobese control group. Methods: A total of 34 adults with obesity who lost 17% body weight at week 13 and maintained this weight loss (WL) at 1 year were compared with 33 nonobese controls matched for body composition. Basal and postprandial subjective appetite ratings and appetite-related hormone concentrations (ghrelin, total peptide YY, peptide YY3-36, total and active glucagonlike peptide 1, and cholecystokinin) were measured in all participants and repeated at week 13 and 1 year in the weight-reduced group. Results: WL led to a reduction in prospective food consumption and an increase in feelings of hunger, fullness, and ghrelin secretion (basal and postprandial), but these new ratings were no different from those seen in controls. Postprandial concentrations of active glucagon-like peptide 1, total peptide YY, and cholecystokinin were lower in individuals with obesity at all time points compared with controls. Conclusion: The increased drive to eat (both subjective feelings of hunger and ghrelin concentrations) seen in reduced-obese individuals, both after acute and sustained WL, reflects a normalization toward a lower body weight. Overall, WL does not have a sustained negative impact on satiety peptide secretion, despite a blunted secretion in individuals with obesity compared with nonobese controls.
KW - Compensation
KW - Ghrelin
KW - Hunger
KW - Normalization
KW - Weight loss
UR - http://www.scopus.com/inward/record.url?scp=85085412199&partnerID=8YFLogxK
U2 - 10.1210/clinem/dgaa202
DO - 10.1210/clinem/dgaa202
M3 - Article
C2 - 32301981
AN - SCOPUS:85085412199
SN - 0021-972X
VL - 105
SP - e2538–e2546
JO - The Journal of Clinical Endocrinology & Metabolism
JF - The Journal of Clinical Endocrinology & Metabolism
IS - 7
ER -
